Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nirmatrelvir

- PMLiVE

NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix

More than 2,000 people in the UK are currently living with the genetic bleeding disorder

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

- PMLiVE

Pfizer shares positive overall survival results for Elrexfio in multiple myeloma

The blood cancer is responsible for more than 187,000 new cases worldwide every year

- PMLiVE

Pfizer/Flagship’s drug discovery partnership to focus on obesity treatments

The agreement with Profound Therapeutics is the first to be initiated under the partnership

- PMLiVE

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

WHA announces progress of WHO Member States to conclude pandemic agreement

The agreement is aimed at preventing a repeat of the global health, economic and social impacts of the COVID-19 pandemic

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Pfizer shares positive five-year results for Lorbrena in advanced lung cancer

The majority of Lorbrena-treated patients were alive without disease progression after five years

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM

Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links